References
- Devenport J, Harper D: Osteoporosis and osteomalacia. In Herfindal ET, Gourley DR, Harr LL, eds: Clinical Pharmacology and Therapeutics. Baltimore: Williams & Wilkins, 1988: 533–541.
- Lane JM, Riley EH, Wirganowicz PZ: Osteoporosis: diagnosis and treatment. J Bone Joint Surg Am 1996; 78: 618–632.
- Krane SM, Holick MF: Metabolic bone disease. In Wilson JD, Braunwald E, Isselbacher KJ, Martin JB, Fauci AS, Kasper DL, eds: Harrison's Principles of Internal Medicine. New York: McGraw-Hill, Inc., 1991: 1921–1926.
- Arnaud CD, Kolb FO: The calcitropic hormones and metabolic bone disease. In Greenspan FS, ed: Basic & Clinical Endocrinology. New York: Appleton & Lange, 1991: 305–311.
- Ruggiero RJ: Gynecologic disorders. In Herfindal ET, Gourley DR, Harr LL, eds: Clinical Pharmacology and Therapeutics. Baltimore: Williams & Wilkins, 1988: 1425–1439.
- Hammond CB: Management of the menopausal woman. American Journal of Managed Care 1996; 5: 541–547.
- Spicer OV, Pike MC: Epidemiology of breast cancer. In Lobo RA, ed: Treatment of Postmenopausal Women: Basic and Clinical Aspects. New York: Raven Press, 1994: 315–324.
- Davis JW, Ross PD, Johnson NE, Wasnich RD: Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination. Bone 1995; 17: 369–373.
- Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437–1443.
- Chestnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tilotson S, Santora AC II: Alendronate treatment of the postmenopausal woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144–152.
- Ashworth L: Focus on alendronate: a nonhormonal option for the treatment of osteoporosis in postmenopausal women. Formulary 1996; 31: 23–30.
- Whitfield JF, Morley P: Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Trends Pharmacol Sci 1995; 16: 382–86.